novo nordisk glp 1 drug GLP-1 Fails to Quell Alzheimer's in Trials Novo Nordisk Is Seeing Slowing

Some studies indicate these drugs can reduce cocaine self-administration and relapse-like drug seeking

Further, a majority of the sample (82.6%) was White/Caucasian, and 80% of participants reported that GLP-1RA use resulted in greater weight loss than conventional programs

Some of them have also been found to be safe and effective to help with weight loss, to treat sleep apnea and to reduce the risk of heart attacks and strokes in people who dont have diabetes

Average Weight Loss in the Orforglipron phase 3 ATTAIN-1 Trial Across the 72-week study period, participants: Lost up to 15% of their body weight at the highest dose At 36 mg: 54.6% lost 10%, 36.0% lost 15%, 18.4% lost 20% body weight (all higher than placebo)

The treatment of interest was new use of GLP-1RA, compared to new use of other non-insulin glucose-lowering agents (new user and active comparator)

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension